Key result
This review summarizes currently approved treatments and a new generation of investigational drugs for pulmonary arterial hypertension, a disease with a median untreated survival of 2.8 years.
Answers are grounded in this paper and cite their sources.
This review provides an update on the pharmacological management of pulmonary arterial hypertension, including approved and investigational therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Velayati et al. (2016) conducted a review in Pulmonary artery hypertension (PAH). Pharmacotherapy was evaluated. This review summarizes currently approved treatments and a new generation of investigational drugs for pulmonary arterial hypertension, a disease with a median untreated survival of 2.8 years.
Synapse has enriched 10 related papers. Consider them for comparative context: